Abstract
Drug resistance is a major impediment to the successful treatment of breast cancer using chemotherapy. The photoactivatable drug calphostin C has shown promise in killing select drug-resistant tumor cells lines in vitro. To assess the effectiveness of this agent in killing doxorubicin- or paclitaxel-resistant breast tumor cells and to explore its mode of action, MCF-7 cells were exposed to increasing concentrations of either doxorubicin or paclitaxel until maximum resistance was obtained. This resulted in the creation of isogenic drug-resistant MCF-7TAX and MCF-7DOX cell lines, which were approximately 50- and 65-fold resistant to paclitaxel and doxorubicin, respectively. Interestingly, calphostin C was able to kill MCF-7TAX cells as efficiently as wildtype MCF-7 cells (IC50s were 9.2 and 13.2 nM, respectively), while MCF-7DOX cells required a 5-fold higher concentration of calphostin C to achieve the same killing (IC50 = 64.2 nM). Consistent with their known mechanisms of action, paclitaxel killed tumor cells by inducing mitotic arrest and cell multinucleation, while doxorubicin induced plasma membrane blebbing and decreased nuclear staining with propidium iodide. In contrast, cytoplasmic vacuolization accompanied cell killing by calphostin C in these cell lines, without the induction of caspase-8 or PARP cleavage or the release of cytochrome c from mitochondria. Calphostin C had little effect on the uptake of either paclitaxel or doxorubicin by the cells. Taken together, the above data suggests that calphostin C is able to potently kill drug-resistant breast tumor cells through a mechanism that may involve the induction of cytoplasmic vacuolization, without activation of typical apoptotic pathways. Consequently, calphostin C may prove useful clinically to combat tumor growth in breast cancer patients whose tumors have become unresponsive to anthracyclines or taxanes, particularly in association with photodynamic therapy.
Similar content being viewed by others
References
Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K: Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol 49: 391–397, 2002
Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58, 2002
Childs S, Ling V: The MDR superfamily of genes and its biological implications. Important Adv Oncol 21–36, 1994
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 258: 1650–1654, 1992
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578–582, 1995
Germann UA: P-glycoprotein-a mediator of multidrug resistance in tumor cells. Eur J Cancer 32A: 927–944, 1996
Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429–433, 1999
Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450–458, 2000
Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51–64, 2001
Fojo A, Akiyama S, Gottesman MM, Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002–3007, 1985
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361–398, 1999
Shabbits J, Krishna R, Mayer L: Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1: 585–594, 2001
Tsuruo T, NaitoM, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N: Molecular targeting therapy of cancer: drug resistance apoptosis and survival signal. Cancer Sci 94: 15–21, 2003
Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205–213, 1992
Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592–6595, 1991
Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666–1674, 1992
Elliott T, Sethi T: Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2: 449–459, 2002
Friesen C, Fulda S, Debatin KM: Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11: 1833–1841, 1997
Cheng A, Chuang S, Fine R, Yeh K, Liao C, Lay J, Chen D: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 55: 523–531, 1998
Clark A, West K, Blumberg P, Dennis P: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 63: 780–786, 2003
Avendano C, Menendez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). CurrMed Chem 9: 159–193, 2002
Fukuda T, Kamishima T, Kakihara T, Ohnishi Y, Suzuki T: Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines. Leuk Res 20: 931–939, 1996
Boesch D, Muller K, Pourtier-Manzanedo A, Loor F: Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26–32, 1991
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F: In vivo circumvention of P-glycoproteinmediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226–4233, 1991
Efferth T, Fabry U, Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 11: 1180–1186, 1997
Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Huntingt) 13: 183–187, 1999
Ogretmen B, Safa AR: Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608–614, 1996
Roninson IB: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, New York, 1991
Sikic BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629–1635, 1993
Fisher GA, Sikic BI: Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363–382, 1995
Fu J, Chen Z, Cen J, Ruan C: Expression of the human multidrug resistance gene mdr1 in leukemic cells and its application in studying P-glycoprotein antagonists. Chin Med J (Engl) 113: 228–231, 2000
Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25: 771–778, 2002
Chadderton A, Villeneuve DJ, Gluck S, Kirwan-rhude AF, Gannon BR, Blais DE, Parissenti AM: Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 59: 231–244, 2000
Crown J: Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 6(Suppl 3): 17–21, 2001
Kobayashi E, Ando K, Nakano H, Iida T, Ohno H, Morimoto M, Tamaoki T: Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) 42: 1470–1474, 1989
Gupta S, Patel K, Singh H, Gollapudi S: Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via Pglycoprotein. Cancer Lett 76: 139–145, 1994
Dubauskas Z, Beck TP, Chmura SJ, Kovar DA, Kadkhodaian MM, Shrivastav M, Chung T, Stadler WM, Rinker-Schaeffer CW: Activated calphostin C cytotoxicity is independent of p53 status and in vivo metastatic potential. Clin Cancer Res 4: 2391–2398, 1998
Beck TP, Kirsh EJ, Chmura SJ, Kovar DA, Chung T, Rinker-Schaeffer CW, StadlerWM: In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology 54: 573–577, 1999
Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT: Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32: 9156–9164, 1993
Matsumoto T, Tani E, Yamaura I, Miyaji K, Kaba K: Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 36: 565–571, 1995
Keating A, Toor P: Human long term bone marrow culture. In: Poclard JM (ed) Wiley Liss, New York, 1990, 331 pp
Martin D, Lenardo M: In: Anonymous (ed), Morphological, Biochemical, and Flow cytometric analysis of apoptosis. Wiley, New York, 2000, pp 1–5
Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 70: 214–220, 1997
Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 13: 134–136, 1992
Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56: 816–825, 1996
Weitzel DH, Vandre DD: Differential spindle assembly checkpoint response in human lung adenocarcinoma cells. Cell Tissue Res 300: 57–65, 2000
Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W: Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198–1211, 2002
Blajeski AL, Kottke TJ, Kaufmann SH: A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270: 277–288, 2001
Serafino A, Sinibaldi-Vallebona P, Pierimarchi P, Bernard P, Gaudiano G, Massa C, Rasi G, Ranagnan G: Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Anticancer Res 19: 1909–1918, 1999
da Silva CP, de Oliveira CR, da Conceicao M, de Lima P: Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem Pharmacol 51: 1331–1340, 1996
Conseil G, Perez-Victoria JM, Jault JM, Gamarro F, Goffeau A, Hofmann J, Di Pietro A: Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry 40: 2564–2571, 2001
Robertson AM, Bird CC, Waddell AW, Currie AR: Morphological aspects of glucocorticoid-induced cell death in human lymphoblastoid cells. J Pathol 126: 181–187, 1978
Sheridan JW, Bishop CJ, Simmons RJ: Biophysical and morphological correlates of kinetic change and death in a starved human melanoma cell line. J Cell Sci 49: 119–137, 1981
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM: Distinct caspase cascades are initiated in receptormediated and chemical-induced apoptosis. J Biol Chem 274: 5053–5060, 1999
Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93: 3053–3063, 1999
Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 9552–9556, 1993
Yvon AM, Wadsworth P, Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10: 947–959, 1999
Tarr M, van Helden PD: Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II a. Mol Cell Biochem 93: 141–146, 1990
Schonwasser DC, Marais RM, Marshall CJ, Parker PJ: Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18: 790, 1998
Ueffing M, Lovri J, Philipp A, Mischak H, Kolch W: Protein kinase C Epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity. Oncogene 15: 2921–2927, 1997
Avruch J, Zhang X, Kyriakis J: Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19: 279–283, 1994
Chapman RS, Whetton AD, Chresta CM, Dive C: Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. Mol Pharmacol 48: 334–343, 1995
Grant S, Jarvis W: Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 2: 1915–1920, 1996
Mayne GC, Murray AW: Evidence that protein kinase Cepsilon mediates phorbol ester inhibition of calphostin C-and tumor necrosis factor-alpha-induced apoptosis in U937 histiocytic lymphoma cells. J Biol Chem 273: 24115–24121, 1998
da Rocha AB, Mans DR, Regner A, Schwartsmann G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7: 17–33, 2002
O'Brian CA, Fan D, Ward NE, Seid C, Fidler IJ: Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett 246: 78–82, 1989
Dong Z, Ward N, Fan D, Gupta K, O'Brian C: In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39: 563–569, 1991
Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially in-fluence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98–104, 1992
Chakrabarty S, Huang S: Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C alpha expression. J Exp Ther Oncol 1: 218–221, 1996
Fine RL, Chambers TC, Sachs CW: P-glycoprotein, multidrug resistance and protein kinase C. Oncologist 1: 261–268, 1996
Masanek U, Stammler G, Volm M: Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2: 37–41, 2002
Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J: Apoptosis of human glioma cells in response to calphostin C, a specific protein kinase C inhibitor. J Neurosurg 83: 1008–1016, 1995
Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM: Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin Cancer Res 4: 2967–2976, 1998
Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707–1714, 1994
Ikemoto H, Tani E, Ozaki I, Kitagawa H, Arita N: Calphostin C-mediated translocation and integration of Bax into mitochondria induces cytochrome c release before mitochondrial dysfunction. Cell Death Differ 7: 511–520, 2000
LaRue JM, Stratagoules ED, Martinez JD: Deoxycholic acidinduced apoptosis is switched to necrosis by bcl-2 and calphostin C. Cancer Lett 152: 107–113, 2000
Sperandio S, de Belle I, Bredesen DE: An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 97: 14376–14381, 2000
Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dorken B, Daniel PT: Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20: 2749–2760, 2001
Janicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357–9360, 1998
Janicke RU, Ng P, Sprengart ML, Porter AG: Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540–15545, 1998
Chambers TC, Pohl J, Raynor RL, Kuo JF: Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem 268: 4592–4595, 1993
Sachs CW, Chambers TC, Fine RL: Differential phosphorylation of sites in the linker region of P-glycoprotein by protein kinase C isozymes alpha, betaI, betaII, gamma, delta, epsilon, eta, and zeta. Biochem Pharmacol 58: 1587–1592, 1999
Chambers T, Chalikonda I, Eilon G: Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 169: 253–259, 1990
Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V, Higgins CF: Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14: 68–75, 1995
Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF: Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271: 13668–13674, 1996
Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM: Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271: 1708–1716, 1996
Sciorra VA, Hammond SM, Morris AJ: Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-C. Biochemistry 40: 2640–2646, 2001
Spinedi A, Oliverio S, Di Sano F, Piacentini M: Calpain involvement in calphostin C-induced apoptosis. Biochem Pharmacol 56: 1489–1492, 1998
Chmura SJ, Nodzenski E, Weichselbaum RR, Quintans J: Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res 56: 2711–2714, 1996
Kobayashi E, Nakano H, Morimoto M, Tamaoki T: Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548–553, 1989
Tamaoki T, Nakano H: Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology 8: 732–735, 1990
Pollack IF, Kawecki S: The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J Neurooncol 31: 255–266, 1997
Hu DE, Fan TP: Protein kinase C inhibitor calphostin C prevents cytokine-induced angiogenesis in the rat. Inflammation 19: 39–54, 1995
Chen CL, Tai HL, Zhu DM, Uckun FM: Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with antileukemic activity. Pharm Res 16: 1003–1009, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Guo, B., Hembruff, S.L., Villeneuve, D.J. et al. Potent Killing of Paclitaxel- and Doxorubicin-resistant Breast Cancer Cells by Calphostin C Accompanied by Cytoplasmic Vacuolization. Breast Cancer Res Treat 82, 125–141 (2003). https://doi.org/10.1023/B:BREA.0000003969.21267.81
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000003969.21267.81